Search

Displaying results 1041 - 1050 of 10000 in total
  1. Drug

    Modified vaccinia ankara

    go.drugbank.com/drugs/DB15483
    ApprovedInvestigational

    Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus.

  2. Drug

    Cresol

    go.drugbank.com/drugs/DB11143
    Approved

    At concentrations normally found in the environment however, cresols do not pose any significant risk for the general population. … Cresol is a hydroxytoluene that can be extracted naturally from coal tar or made synthetically. Pure cresol is a mixture of ortho-, meta-, and para- isomers.

  3. Drug

    Lisuride

    go.drugbank.com/drugs/DB00589
    Approved

    An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). … It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).

  4. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    [A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors … Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.

    Categories: Dopamine D2 Receptor Antagonists
  5. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms. … Levomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773].

    Mixtures: Hematron-AF, Hematron-AF
  6. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored odorless powder. … Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation.

  7. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    eliglustat, represent a treatment alternative. … [L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.

  8. Drug

    Astemizole

    go.drugbank.com/drugs/DB00637
    ApprovedWithdrawn

    It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. … Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms.

    Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index
  9. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine.

    International brands: PropycilProducts: PROPYCIL 50 MG TABLET, 20 ADET
  10. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor.